Development of new functional artificial virus contained cancer-selective anticancer drug with the cancer-specific molecules

• Project/Area Number: 22791255
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: General surgery
• Research Institution: Kyushu University
• Principal Investigator: ONIMARU Manabu 九州大学, 医学研究院, 共同研究員 (80529876)
• Project Period (FY): 2010 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 膵癌 / 人工ウイルス

Research Abstract

We can create a multi-functional artificial virus contained cancer-specific anti-cancer drug. We also evaluated the form and function of this new virus in vitro. We confirmed that artificial virus had been specifically-taken into the pancreatic cancer cell line and had a certain therapeutic effect in comparative experiments in pancreatic cancer cell lines and normal cells in vitro.

Research Products

• [Journal Article] Tanaka M Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil (2011)
  • Author(s): Kurata N, Fujita H, Ohuchida K, Mizumoto K, Mahawithitwong P, Sakai H, Onimaru M, Manabe T, Ohtsuka T
  • Journal Title: Int J Oncol Volume: 39(2) Pages: 473-82
  • Peer Reviewed
• [Journal Article] Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells (2011)
  • Author(s): Yasui T, Ohuchida K, Zhao M, Cui L, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto M, Matsumoto K, Tanaka M
  • Journal Title: Anticancer Res Volume: 31(4) Pages: 1279-88
  • Peer Reviewed
• [Journal Article] Tanaka M High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy (2011)
  • Author(s): Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Hayashi A, Souzaki R, Tajiri T, Onimaru M, Manabe T, Ohtsuka T
  • Journal Title: Int J Oncol Volume: 38(3) Pages: 629-41
  • Peer Reviewed
• [Journal Article] Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway (2011)
  • Author(s): Yasui T, Ohuchida K, Zhao M, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K, Tanaka M
  • Journal Title: Cancer science Volume: 102(2) Pages: 484-91
  • NAID: 10029290639
  • Peer Reviewed
• [Journal Article] Gencitabime synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in (2010)
  • Author(s): Onimaru M, Ohuchida K, Egami T, Mizumoto K, Nagai E, Cui L, Toma H, Matsumoto K, Hashizume M, Tanaka M.
  • Journal Title: pancreatic cancer cells Cancer Gene Ther Volume: 17(8) Pages: 541-9
  • Peer Reviewed
• [Journal Article] Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer (2010)
  • Author(s): Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, Sato N, Uchino J, Takayama K, Hashizume M, Tanaka M.
  • Journal Title: Cancer Lett. Volume: 294(2) Pages: 178-86
  • Peer Reviewed